ClinicalTrials.gg
CompletedNCT02609659GEODE IIUpdated Dec 10, 2019Results posted

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

A Phase 3 interventional study of ombitasvir/paritaprevir/ritonavir and dasabuvir and ribavirin in Hepatitis C Virus (HCV), sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-10.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing ombitasvir in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. ombitasvir · Hepatitis C.

Enrollment
17th of 26
105 · median 143
Started
2015
with 8 others
Phase 3
15 of 26
none open now
Registered
25th of 26
by date
Lead sponsor
12 of 26
AbbVie

Among the 26 studies testing ombitasvir in Hepatitis C, this one is the 17th largest by enrollment, is one of 9 that started in 2015, is one of 15 in phase 3, and was the 25th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 26 studies testing ombitasvir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ombitasvir

ombitasvir: first FDA approval 2014 (VIEKIRA PAK (COPACKAGED)), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing ombitasvir in Hepatitis C as a file.
02

Study summary

This study seeks to assess the safety and efficacy of treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in non-cirrhotic, genotype 1a (GT1a) hepatitis C virus infected participants who are treatment-naïve or treatment-experienced with Interferon (IFN) or Pegylated Interferon (pegIFN) with or without Ribavirin (RBV).

03

Conditions studied

  • Hepatitis C Virus (HCV)

Browse trials for

Keywords

  • Chronic Hepatitis C Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic virus (HCV) infection
  • Non-cirrhotic subjects
  • Screening laboratory results showing HCV Genotype 1a (HCV GT1a) infection
  • HCV treatment-naïve or if treated previously, only with interferon (IFN) or pegylated interferon (pegINF) with or without ribavirin (RBV)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Positive for surface antigen (HBsAg) or anti- antibody (HIV Ab)
  • genotype of any subtype other than GT1a or unable to subtype
  • Prior or current use of any or commercially available anti-HCV agents other than IFN, pegIFN or RBV. Subjects with previous participation in trials of investigational direct-acting antiviral agents (DAAs) may be enrolled if they can produce documentation that they received only placebo.
  • Current enrollment in another interventional clinical study or receipt of any investigational product within 6 weeks prior to study drug administration.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    3-DAA + RBV 600 mg

    3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) plus RBV (ribavirin \[600 mg once daily\]) for 12 weeks.

    Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir · Drug: ribavirin

Interventions

  • Drugombitasvir/paritaprevir/ritonavir and dasabuvir

    Drug pages: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir

    Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

    Also known as: Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333

  • Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of participants who achieved SVR12 in participants in the treatment arm 3-DAA + RBV 600 mg) for 12 weeks compared with the historical control rate for subjects treated with 3-DAA + weight-based RBV for 12 weeks.

    Time frame: 12 weeks after the last actual dose of study drug

  2. Percentage of Participants With Hemoglobin < 10 g/dL During Treatment

    The percentage of participants with hemoglobin \<10 g/dL during treatment is provided.

    Time frame: up to 12 weeks

  3. Mean Change in Hemoglobin Values From Baseline to End of Treatment

    The mean change in hemoglobin (g/L) from baseline to each study visit and to the final treatment visit (up to 12 weeks) is provided.

    Time frame: Baseline (Day 1) to Weeks 2, 4, 8, and 12, and the Final Treatment Visit (up to 12 weeks)

Secondary outcomes

  1. Percentage of Participants With On-treatment Virologic Failure

    On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment.

    Time frame: Up to 12 weeks

  2. Percentage of Participants With Post-treatment Relapse

    Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug, excluding reinfection, among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.

    Time frame: From the end of treatment through 12 weeks after the last dose of study drug

07

Results

Posted Oct 18, 2017

Participant flow

Participant flow — Overall Study
Milestone3-DAA + RBV 600 mg
Started105
Completed97
Not completed8
Withdrew: Adverse event1
Withdrew: Lost to follow-up6
Withdrew: Other1

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)

SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \[\<LLOQ\]) 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of participants who achieved SVR12 in participants in the treatment arm 3-DAA + RBV 600 mg) for 12 weeks compared with the historical control rate for subjects treated with 3-DAA + weight-based RBV for 12 weeks.

Time frame:
12 weeks after the last actual dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
percentage of participants3-DAA + RBV 600 mg
Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)89.5 (83.7 to 95.4)
Statistical analysis
  • 3-DAA + RBV 600 mg · Percentage of participants: 89.5 · 95% CI 83.7 to 95.4
PrimaryPercentage of Participants With Hemoglobin < 10 g/dL During Treatment

The percentage of participants with hemoglobin \<10 g/dL during treatment is provided.

Time frame:
up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Hemoglobin < 10 g/dL During Treatment
percentage of participants3-DAA + RBV 600 mg
Percentage of Participants With Hemoglobin < 10 g/dL During Treatment0
PrimaryMean Change in Hemoglobin Values From Baseline to End of Treatment

The mean change in hemoglobin (g/L) from baseline to each study visit and to the final treatment visit (up to 12 weeks) is provided.

Time frame:
Baseline (Day 1) to Weeks 2, 4, 8, and 12, and the Final Treatment Visit (up to 12 weeks)
Reported as:
Mean · g/L
Mean Change in Hemoglobin Values From Baseline to End of Treatment
g/L3-DAA + RBV 600 mg
Week 2-6.4 ± 8.17
Week 4-8.9 ± 9.37
Week 8-11.2 ± 9.85
Week 12-12.4 ± 10.06
Final Treatment Visit-12.1 ± 9.90
SecondaryPercentage of Participants With On-treatment Virologic Failure

On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \< LLOQ during treatment; confirmed increase of \> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment.

Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With On-treatment Virologic Failure
percentage of participants3-DAA + RBV 600 mg
Percentage of Participants With On-treatment Virologic Failure1.0
SecondaryPercentage of Participants With Post-treatment Relapse

Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug, excluding reinfection, among participants who completed treatment with HCV RNA levels \< LLOQ at the end of treatment.

Time frame:
From the end of treatment through 12 weeks after the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Post-treatment Relapse
percentage of participants3-DAA + RBV 600 mg
Percentage of Participants With Post-treatment Relapse4.1

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 30 days after the last dose of study drug (up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3-DAA + RBV 600 mg—3/105 (2.9%)53/105 (50.5%)
Most frequent serious events
Most frequent serious events
Event3-DAA + RBV 600 mg
CYCLIC VOMITING SYNDROMEGastrointestinal disorders1/105
BIPOLAR I DISORDERPsychiatric disorders1/105
PSYCHOTIC DISORDERPsychiatric disorders1/105
Most frequent other events
Most frequent other events
Event3-DAA + RBV 600 mg
FATIGUEGeneral disorders29/105
HEADACHENervous system disorders14/105
INSOMNIAPsychiatric disorders12/105
NAUSEAGastrointestinal disorders11/105
DIARRHOEAGastrointestinal disorders9/105
ANXIETYPsychiatric disorders7/105
CONSTIPATIONGastrointestinal disorders6/105
INFLUENZAInfections and infestations6/105
BACK PAINMusculoskeletal and connective tissue disorders6/105

Baseline characteristics

Age, Continuous
Age, Continuous(years)3-DAA + RBV 600 mg
Mean49.8 ± 13.03
Sex: Female, Male
Sex: Female, Male(Participants)3-DAA + RBV 600 mg
Female55
Male50
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Poordad F, Sedghi S, Pockros PJ, Ravendhran N, Reindollar R, Lucey MR, Epstein M, Bank L, Bernstein D, Trinh R, Krishnan P, Polepally AR, Unnebrink K, Martinez M, Nelson DR. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. J Viral Hepat. 2019 Aug;26(8):1027-1030. doi: 10.1111/jvh.13109. Epub 2019 May 6. PubMed 30980576 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Oct 2016, 11 months.

Results were first posted in Oct 2017, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2015
First posted
Nov 20, 2015
StartActual
Oct 28, 2015
Primary completionActual
Oct 7, 2016
CompletionActual
Dec 28, 2016
Results first posted
Oct 18, 2017
Last update
Dec 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02609659
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 20, 2015
Start date
Oct 28, 2015
Primary completion
Oct 7, 2016
Completion
Dec 28, 2016
Results posted
Oct 18, 2017
Last update
Dec 10, 2019

Study contacts

AbbVie Inc
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ombitasvir · Paritaprevir · Ritonavir · Dasabuvir · Ribavirin

Start the discussion